In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Keytruda LoE: A seismic shift for oncology?
Immune checkpoint inhibitors (ICIs) have changed the face of oncology treatment since their initial entry in the early 2010s. Driven mostly by the group of...